BioAffinity Technologies Shares Surge Following Hong Kong Patent Grant

Key Facts

1BioAffinity Technologies shares surged after securing a Hong Kong patent for its CyPath Lung diagnostic.

In a move reflecting the international expansion of emerging biotech firms, BioAffinity Technologies shares experienced a significant surge. According to reports, this price action followed the company's announcement that it secured a patent in Hong Kong for its flagship CyPath Lung diagnostic tool. The grant provides essential intellectual property protection in a major market, strengthening the position of its core diagnostic technology.

This positive development comes as medical diagnostic companies prioritize securing their innovations globally. Based on available data, a patent grant in a new jurisdiction is a fundamental milestone for micro-cap biotech firms, typically driving increased retail interest. The company relies heavily on the success of CyPath Lung to fuel its future growth trajectory.

Regarding stock performance, BIAF closed at $5.35 (close September 16, 2026), after reaching a session high of $6.31. With no immediate healthcare-specific catalysts in the upcoming economic calendar, investors will watch if the price momentum can hold above the support level established at the September 16 low of $5.11.